Growth factor receptor expression in orbital lymphangioma: Possible therapeutic implications

Orbit

Volumn 23, Issue 4, 2004, Pages 263-269

  Esmaeli, Bita ^a   Prieto, Victor G ^a   Gonnering, Russell ^b   Hawes, Michael J ^c   Diba, Roxana ^a   Saadati, Hossein G ^a   Shepler, Todd R ^a   Karcioglu, Zeynel ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EYE INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISOLONE; STEM CELL FACTOR;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHANGIOMA; MALE; MAST CELL; ORBIT TUMOR; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOOTH MUSCLE FIBER;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ENDOTHELIUM, VASCULAR; FEMALE; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOMA; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; ORBITAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RETROSPECTIVE STUDIES;

EID: 10844245744     PISSN: 01676830     EISSN: None     Source Type: Journal    
DOI: 10.1080/01676830590889875     Document Type: Article

References (24)

1. Iliff WJ, Green WR. Orbital lymphangiomas. Ophthalmology. 1979;86:914-929.
2. Harris GJ, Sakol PJ, Bonavolonta G, De Conciliis C. An analysis of thirty cases of orbital lymphangioma. Ophthalmology. 1990;97:1583-1592.
3. Tunc M, Sadri E, Char DH. Orbital lymphangioma: an analysis of 26 patients. Br J Ophthalmol. 1999;83:76-80.
4. Wilson ME, Parker PL, Chavis RM. Conservative management of childhood orbital lymphangioma. Ophthalmology. 1989;96:484-490.
5. Sires BS, Goins CR, Anderson RL, Holds JB. Systemic corticosteroid use in orbital lymphangioma. Ophthal Plast Reconstr Surg. 2000;17:85-90.
6. Wojno TH. Sotradecol (sodium tetradecyl sulfate) injection of orbital lymphangioma. Ophthal Plast Reconstr Surg. 1999;15:432-437.
7. Suzuki Y, Obana A, Gohto Y, et al. Management of orbital lymphangioma using intralesional injection of OK-432. Br J Ophthalmol. 2000;84:614-617.
8. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist. 2001;6:233-238.
9. Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology. 2002;16(suppl 9):19-24.
10. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effects of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
12. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Exp Opin Invest Drugs. 2003;12:51-64.
13. Baselga J, Hammond LA. HER-targeted tyrosine-kinase inhibitors. Oncology. 2002;63(suppl 1):6-16.
14. Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 2002;8:3496-3502.
15. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys. 2002;54:1180-1193.
16. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 2001;23:494-507.
17. Hughes AD, Clunn GF, Refson J, et al. Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gen Pharmacol. 1996;27:1079-1089.
18. Beitz JG, Kim IS, Calabresi P, et al. Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci USA. 1991;88:2021-2025.
19. Jin J, Zhu SJ, Zhu ZM, et al. Relationship between proliferation of vascular smooth muscle cells and PDGF-AA and PDGFR-alpha expression in SHRs. Sheng Li Xue Bao. 2002;54:145-148.
20. Lindqvist A, Nilsson BO, Ekblad E, Hellstrand P. Platelet-derived growth factor receptors expressed in response to injury of differentiated vascular smooth muscle in vitro: effects on Ca2+ and growth signals. Acta Physiol Scand. 2001;173:175-184.
21. Bohling T, Hatva E, Kujala M, et al. Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol. 1996;55:522-527.
22. Cursiefen C, Schlotzer-Schrehardt U, Breiteneder-Geleff S, Holbach LM. Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin). Graefe's Arch Clin Exp Ophthalmol. 2001;239:628-632.
23. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95:881-887.
24. He H, Levitzki A, Zhu HJ, et al. Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J Biol Chem. 2001;276:2671-2674.